The Food and Drug Administration (FDA) has approved Uplizna ® (inebilizumab-cdon) for the treatment of immunoglobulin G4-related disease (IgG4-RD) in adult patients.

Inebilizumab-cdon was previously approved by the FDA for neuromyelitis optica spectrum disorder (NMOSD) in adults who are ...

Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.